Values of Ga-DOTATOC and Carbidopa-assisted F-DOPA PET/CT for insulinoma localization.

Fiche publication

Date publication

juillet 2021

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio

Tous les auteurs :
Imperiale A, Boursier C, Sahakian N, Ouvrard E, Chevalier E, Sebag F, Addeo P, Taïeb D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34272321

Résumé

To assess the value of Ga-DOTATOC and carbidopa-assisted F-DOPA in 21 hypoglycaemic patients. All patients who underwent Ga-DOTATOC and/or carbidopa-assisted F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analysed. Insulinoma final diagnosis was defined according to pathological reports or consensus. During the study period, 21 patients underwent both Ga-DOTATOC and F-DOPA PET/CT. A final diagnosis of insulin-secreting tumour was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/non-neuroendocrine neoplasm. F-DOPA and Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by F-DOPA PET/CT and 3 by Ga-DOTATOC PET/CT only. F-DOPA and Ga-DOTATOC PET/CT were falsely positive in 1 non-functioning pancreatic neuroendocrine tumour. When Ga-exendin-4 is not available, Ga-SSTR PET/CT should be the first choice for insulinoma functional imaging.